Preclinical evaluation of alternatives to oral immunotherapy for food allergies

The increasing food allergy incidence has led to significant interest in developing therapies for allergic diseases. Oral allergen-specific immunotherapy (OIT) is a recently FDA-approved therapeutic to treat peanut allergies. OIT utilizes daily allergen dosing to reduce allergic reactions to peanuts...

Full description

Bibliographic Details
Main Author: Brandi T. Johnson-Weaver
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Allergy
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/falgy.2023.1275373/full
_version_ 1797667805611425792
author Brandi T. Johnson-Weaver
author_facet Brandi T. Johnson-Weaver
author_sort Brandi T. Johnson-Weaver
collection DOAJ
description The increasing food allergy incidence has led to significant interest in developing therapies for allergic diseases. Oral allergen-specific immunotherapy (OIT) is a recently FDA-approved therapeutic to treat peanut allergies. OIT utilizes daily allergen dosing to reduce allergic reactions to peanuts. However, there is diminished enthusiasm for daily OIT, potentially due to the strict regimen required to induce desensitization and the risks of severe adverse events. Thus, there remains a need for safe and effective food allergy treatments that are well-received by allergic individuals. Preclinical research studies investigate methods to induce allergen desensitization in animals and support clinical studies that address the limitations of current food allergy OIT. Because allergic reactions are triggered by allergen doses above an individual's activation threshold, immunotherapy regimens that induce allergen desensitization with lower allergen doses or without the requirement of daily administrations may expand the use of food allergy immunotherapy. Administering allergen immunotherapy by alternative routes is a strategy to induce desensitization using lower allergen doses than OIT. Several animal models have evaluated oral, sublingual, epicutaneous, and intranasal immunotherapy routes to treat food allergies. Each immunotherapy route may require different allergen doses, formulations, and treatment schedules to induce desensitization. This article will discuss scientific findings from food allergy immunotherapy animal studies that utilize various immunotherapy routes to induce allergen desensitization to support future clinical studies that enhance the safety and efficacy of allergen immunotherapy to treat food allergies.
first_indexed 2024-03-11T20:18:29Z
format Article
id doaj.art-e1abc63d88a546e6a22dcf5a838d610a
institution Directory Open Access Journal
issn 2673-6101
language English
last_indexed 2024-03-11T20:18:29Z
publishDate 2023-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Allergy
spelling doaj.art-e1abc63d88a546e6a22dcf5a838d610a2023-10-03T10:02:04ZengFrontiers Media S.A.Frontiers in Allergy2673-61012023-10-01410.3389/falgy.2023.12753731275373Preclinical evaluation of alternatives to oral immunotherapy for food allergiesBrandi T. Johnson-WeaverThe increasing food allergy incidence has led to significant interest in developing therapies for allergic diseases. Oral allergen-specific immunotherapy (OIT) is a recently FDA-approved therapeutic to treat peanut allergies. OIT utilizes daily allergen dosing to reduce allergic reactions to peanuts. However, there is diminished enthusiasm for daily OIT, potentially due to the strict regimen required to induce desensitization and the risks of severe adverse events. Thus, there remains a need for safe and effective food allergy treatments that are well-received by allergic individuals. Preclinical research studies investigate methods to induce allergen desensitization in animals and support clinical studies that address the limitations of current food allergy OIT. Because allergic reactions are triggered by allergen doses above an individual's activation threshold, immunotherapy regimens that induce allergen desensitization with lower allergen doses or without the requirement of daily administrations may expand the use of food allergy immunotherapy. Administering allergen immunotherapy by alternative routes is a strategy to induce desensitization using lower allergen doses than OIT. Several animal models have evaluated oral, sublingual, epicutaneous, and intranasal immunotherapy routes to treat food allergies. Each immunotherapy route may require different allergen doses, formulations, and treatment schedules to induce desensitization. This article will discuss scientific findings from food allergy immunotherapy animal studies that utilize various immunotherapy routes to induce allergen desensitization to support future clinical studies that enhance the safety and efficacy of allergen immunotherapy to treat food allergies.https://www.frontiersin.org/articles/10.3389/falgy.2023.1275373/fullfood allergyimmunotherapymouse modelsimmunotherapy routeimmune modulation
spellingShingle Brandi T. Johnson-Weaver
Preclinical evaluation of alternatives to oral immunotherapy for food allergies
Frontiers in Allergy
food allergy
immunotherapy
mouse models
immunotherapy route
immune modulation
title Preclinical evaluation of alternatives to oral immunotherapy for food allergies
title_full Preclinical evaluation of alternatives to oral immunotherapy for food allergies
title_fullStr Preclinical evaluation of alternatives to oral immunotherapy for food allergies
title_full_unstemmed Preclinical evaluation of alternatives to oral immunotherapy for food allergies
title_short Preclinical evaluation of alternatives to oral immunotherapy for food allergies
title_sort preclinical evaluation of alternatives to oral immunotherapy for food allergies
topic food allergy
immunotherapy
mouse models
immunotherapy route
immune modulation
url https://www.frontiersin.org/articles/10.3389/falgy.2023.1275373/full
work_keys_str_mv AT branditjohnsonweaver preclinicalevaluationofalternativestooralimmunotherapyforfoodallergies